Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, which is frequently present in patients with atherosclerosis or its complications (myocardial infarction, stroke). Subsequently it was revealed that NAFLD may increase cardiovascular risk independently of traditional cardiovascular risk factors. Possible mechanisms of NAFLD-induced increasing cardiovascular risk are increased oxidative stress, subclinical inflammation, insulin resistance, endothelial dysfunction and deranged аdipocytokines profile. Such risk factors as arterial hypertension, dyslipidemia, obesity, diabetes mellitus type 2 often coexist with NAFLD and contribute to increased cardiovascular risk in these patients. Thus, NAFLD can be considered as an additional risk factor of cardiovascular diseases. In this article we discuss in detail the NAFLD-induced mechanisms which increase the cardiovascular risk regardless of traditional risk factors.

About the Authors

O. M. Drapkina
National Medical Research Center for Preventive Medicine
Russian Federation

Oksana M. Drapkina – MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Director.

Petroverigsky per. 10-3, Moscow, 101990

A. A. Yafarova
I.M. Sechenov First Moscow State Medical University
Russian Federation

Adel A. Yafarova – 6-th Year Student, Center for Innovative Programs "Medicine of the Future".

Trubetskaya ul. 8-2, Moscow, 119991


1. Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease current status and future directions. J Dig Dis. 2015;16(10):541-57. doi: 10.1111/1751-2980.12291.

2. Masarone M, Federico A, Abenavoli L, al. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials. 2014;9(3):126-33. 10.2174/1574887109666141216111143

3. Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des. 2013;19(29):5169-76. 10.2174/13816128113199990336

4. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524-30. doi: 10.1016/j.cgh.2011.03.020.

5. Neuschwander-Tetri B.A. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1):45. doi: 10.1186/s12916-017-0806-8.

6. Ress C, Kaser S. Mechanisms of intrahepatic triglyceride accumulation. World J Gastroenterol. 2016;22(4):1664-73. doi: 10.3748/wjg.v22.i4.1664.

7. de Castro GS, Calder PC. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clin Nutr. 2017 Jan 19. pii: S0261-5614(17)30011-0. doi: 10.1016/j.clnu.2017.01.006.

8. Tilg H., Diehl A., Li Z., et al. Cytokines and the pathogenesis of nonalcoholic steatohepatitis. Gut. 2005;54:303-6. doi: 10.1136/gut.2003.024935

9. Xu X, Lu L, Dong Q et al. Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis. Lipids Health Dis. 2015 Dec 3;14:158. doi: 10.1186/s12944-015-0141-z.

10. Milner K., Van der Poorten D., Xu A., et al. Adipocyte fatty acid binding protein levels relate to inflammation andfibrosis in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1926-34. doi: 10.1002/hep.22896.

11. Cnop M., Havel P., Utzschneider K. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasms lipoproteins: evidence for independent roles ofage and sex. Diabetologia. 2003;46:459-69. doi: 10.1007/s00125-003-1074-z

12. Pisto P, Santaniemi M, Bloigu R, et al. Fatty liver predicts the risk for cardiovascular events in middleaged population: a population-based cohort study. BMJ Open. 2014;4(3):e004973. doi: 10.1136/bmjopen-2014-004973.

13. Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci. 2011;56(12):3439-49. doi: 10.1007/s10620-011-1767-y.

14. Zhang QQ, Lu LG. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol. 2015;3(1):78-84. doi: 10.14218/JCTH.2014.00037.

15. Azzam H, Malnick S. Non-alcoholic fatty liver disease the heart of the matter. World J Hepatol. 2015;7(10):1369-76. doi: 10.4254/wjh.v7.i10.1369.

16. Almeda-Valdes P, Altamirano-Barrera A, Méndez-Sánchez N. Insights in non-alcoholic fatty liver disease pathophysiology with lipidomic analyses. Ann Hepatol. 2015;14(4):567-9.

17. Ress C, Kaser S. Mechanisms of intrahepatic triglyceride accumulation. World J Gastroenterol. 2016;22(4):1664-73. doi: 10.3748/wjg.v22.i4.1664.

18. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119-21. doi: 10.2337/dc07-0349

19. Radu C, Grigorescu M, Crisan D, et al. Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis. 2008;17:255-60.

20. Tenenbaum A, Klempfner R, Fisman EZ. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol. 2014;13:159. doi: 10.1186/s12933-014-0159-y.

21. Polyzos SA, Aronis KN, Kountouras J, et al. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016;59(1):30-43. doi: 10.1007/s00125-015-3769-3.

22. Drapkina O.M., Korneeva O.N. Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Rational Pharmacotherapy in Cardiology. 2016;12(4):424-9. (In Russ) [Драпкина О.М., Корнеева О.Н. Континуум неалкогольной жировой болезни печени: от стеатоза печени до сердечно-сосудистого риска. Рациональная Фармакотерапия в Кардиологии. 2016;12(4):424-429]. doi: HYPERLINK""10.20996/1819-6446-2016-12-4-424-429

23. Kazyulin A.N. Place of ursodeoxycholic acid in the therapy of non-alcoholic fatty liver disease at different stages of the disease: steatosis, steatohepatitis, fibrosis / cirrhosis. Russkij Medicinskij Zhurnal. 2017;17:1248-57. (In Russ.) [Казюлин А.Н. Место урсодезоксихолевой кислоты в терапии неалкогольной жировой болезни печени на разных стадиях заболевания: стеатоз, стеатогепатит, фиброз/цирроз. Русский Медицинский Журнал. 2017;17:1248-57]. Disclosures. Help to publish of the article provided PRO.MED.CS Praha a.s., but it did not affect his own opinion of the authors.

24. Ivashkin V.T. Nuclear receptors and liver pathology. Part 2. Rossijskij Zhurnal Gastrojenterologii, Gepatologii i Koloproktologii. 2010;4:7-15. (In Russ.) [Ивашкин В.Т. Ядерные рецепторы и патология печени. Часть 2. Российский Журнал Гастроэнтерологии, Гепатологии и Колопроктологии. 2010;4:7—15].

25. Sugino I, Kuboki K, Matsumoto T, et al. Influence of fatty liver on plasma small, dense LDLcholesterol in subjects with and without metabolic syndrome. J Atheroscler Thromb. 2011;18(1):1-7. Doi: 10.5551/jat.5447

26. Kassner U, Schlabs T, Rosada A, Steinhagen-Thiessen E. Lipoprotein(a)—An independent causal risk factor for cardiovascular disease and current therapeutic options. Atheroscler Suppl. 2015;18:263-7. doi: 10.1016/j.atherosclerosissup.2015.02.039.

27. Lee S, Jin Kim Y, Yong Jeon T, et al. Obesity ishe only independent factor associated with ultrasounddiagnosed non-alcoholic fatty liverdisease: a cross-sectional case-control study. Scand J Gastroenterol. 2006;41(5):566-72. doi: 10.1080/00365520500319591

28. Yang MH, Son HJ, Sung JD, et al. The relationship between apolipoprotein E polymorphism, lipoprotein (a) and fatty liver disease. Hepatogastroenterology. 2005;52(66):1832-5.

29. Wu CL, Zhao SP, Yu BL. Intracellular role of exchangeable apolipoproteins in energy homeostasis, obesity and non-alcoholic fatty liver disease. Biol Rev Camb Philos Soc. 2015;90(2):367-76. doi: 10.1111/brv.12116.

30. Tilg H, Moschen A. Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation. Curr Opin Clin Nutr Metab Care. 2010;13(4):391-6. doi: 10.1097/MCO.0b013e32833a87cc.

31. Forte TM, Sharma V, Ryan RO. Apolipoprotein A-V gene therapy for disease prevention / treatment: a critical analysis. J Biomed Res. 2016;30(2):88-93. doi: 10.7555/JBR.30.20150059.

32. Bonci E, Chiesa C, Versacci P, et al. Association of Nonalcoholic Fatty Liver Disease with Subclinical Cardiovascular Changes: A Systematic Review and Meta-Analysis. Biomed Res Int. 2015;2015:213737. doi: 10.1155/2015/213737.

33. Valbusa F, Bonapace S, Grillo C, et al. Nonalcoholic Fatty Liver Disease Is Associated With Higher 1year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure. Medicine (Baltimore). 2016;95(7):e2760. doi: 10.1097/MD.0000000000002760.

34. Talman AH, Psaltis PJ, Cameron JD, et al. Epicardial adipose tissue: far more than a fat depot. Cardiovasc Diagn Ther. 2014;4(6):416-29. doi: 10.3978/j.issn.2223-3652.2014.11.05.

35. Ozel Coskin B.D., Yucesov M., Gursoy S., et al. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2015;27(2):142-9. doi: 10.1097/MEG.0000000000000264.

36. Bhatia L, Scorletti E, Curzen N, et al. Improvement in nonalcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. Atherosclerosis. 2016;246:13-20. doi: 10.1016/j.atherosclerosis.2015.12.028.

37. Mueller M., Thorrel A., Claudel T., et al. Ursodeoxycholic acid exerts farnesoid X receptor antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol. 2015;62(6):1398-404. doi: 10.1016/j.jhep.2014.12.034.

38. Petta S, Argano C, Colomba D, et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol. 2015;62(4):928-33. doi: 10.1016/j.jhep.2014.11.030.

39. Alp H, Karaarslan S, Selver Eklioglu B, et al. Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. Can J Cardiol. 2013;29(9):1118-25. doi: 10.1016/j.cjca.2012.07.846.

40. Iacobellis G, Barbarini G, Letizia C, Barbaro G. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity. 2014;22(2):332-6. doi: 10.1002/oby.20624 .

41. Sunbul M, Agirbasli M, Durmus E, et al. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis. 2014;237(2):490-3. doi: 10.1016/j.atherosclerosis.2014.10.004 .

42. Petta S, Argano C, Colomba D, et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. Journal of Hepatology. 2015;62(4):928-33. doi: 10.1016/j.jhep.2014.11.030 .

43. Fracanzani AL, Pisano G, Consonni D, et al. Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. PLoS ONE. 2016;11(9):e0162473. doi:10.1371/journal.pone.0162473.

For citation:

Drapkina O.M., Yafarova A.A. NON-ALCOHOLIC FATTY LIVER DISEASE AND CARDIOVASCULAR RISK: SCIENTIFIC PROBLEM STATE. Rational Pharmacotherapy in Cardiology. 2017;13(5):645-650. (In Russ.)

Views: 253

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)